

**Remarks/Arguments:**

Minor errors were noted in Table 1 of the specification. These errors are considered obvious errors that do not constitute new matter because one skilled in the art would not only recognize the existence of the errors, but would also recognize the appropriate correction. Applicant has attached a Rule 132 Declaration from Leslie A. Confer to support this position. And appropriate amendments have been made to Table 1 in accordance with the Confer Declaration to correct the errors.


New claims 46-59 do not include new matter. The term active fractions finds support in the specification. Initially, the term "egg product" is defined defined to mean whole egg or any product or fraction derived therefrom (see page 11, lines 4-6). The specification then describes that various fractions of the egg can be used in the invention (see page 13, lines 1-14 and page 19 line 15 through page 20, line 34). Applicants have used the word "active" in the claim in order to make it clear that only a fraction of egg having anti-inflammatory activity would be effective.

In support of the position that fractions of the hyperimmune egg, other than whole egg, are also effective in producing a synergistic anti-inflammatory effect when combined with glucosamine, Applicants have attached a Rule 132 Declaration from Dr. Subramanian Iyer wherein he describes additional data developed in support of this position.

In view of the data presented in the Iyer 132 Declaration, it is applicant's position that there is clearly support for the language in new claims 46-59. In particular, it is applicant's position that this data supports that any active fraction of a hyperimmune egg will induce a synergistic anti-inflammatory effect when combined with glucosamine.

Applicants respectfully request that these amendments be entered prior to examination of the application. Should the Examiner have any questions, applicants encourage that the Examiner please contact the undersigned at 302-778-2500.

Respectfully submitted,



---

Basil S. Krikelis, Registration No. 41,129  
Attorney for Applicant


BSK/rls

Dated: March 26, 2004

☒ P.O. Box 1596  
Wilmington, DE 19899  
(302) 778-2600

The Commissioner for Patents is hereby authorized to charge payment to Deposit Account No. **18-0350** of any fees associated with this communication.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on: March 26, 2004



---

Ruth Curran

---